Navigation Links
Dr. Charles Sanders to Become Lead Director of Epiphany Biosciences
Date:10/2/2008

SAN FRANCISCO, Oct. 2 /PRNewswire-FirstCall/ -- Epiphany Biosciences, Inc. announced today that Dr. Charles Sanders has accepted the position of Lead Director. Dr. Sanders is a highly experienced biotechnology and pharmaceutical executive, currently serving as Lead Director of Genentech. He has also served as chief executive officer of Glaxo Inc., from 1989-1994 and chairman of the board from 1992-1995. In addition, Dr. Sanders is also a member of the Boards of Directors of Vertex Pharmaceuticals, Cephalon, Inc., and Icagen, Inc.

"The Epiphany strategy of addressing long-term disease as sequelae of chronic viral infection offers a unique perspective in addressing unmet medical needs in a variety of patients. Dr. Volinsky has assembled an outstanding team and I am happy to work with them to reach their goals," reported Dr. Sanders.

"We are elated to have Dr. Sanders as our Lead Director. His extensive experience in the biotechnology industry has already helped propel Epiphany forward and we look forward to his continued input and counsel," stated Fred Volinsky, MD, the Chief Executive Officer of Epiphany Biosciences.

"Next year will be a critically important time for the company as we plan to collect data from up to four Phase 2 studies as well as continue further development of our HCV pipeline," commented Brian Murphy, MD, Chief Medical Officer of Epiphany. "Dr. Sanders' guidance will be very valuable at this pivotal time."

About Epiphany Biosciences:

Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella virus (VZV), Epstein-Barr Virus (EBV) and hepatitis C virus (HCV).

Contact:

Fred Volinsky

CEO of Epiphany Biosciences, Inc.

+1-415-765-7193


'/>"/>
SOURCE Epiphany Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Charles C. Harwood, Jr., Joins Cellectar, Inc.s Board of Directors
2. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
3. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
4. Dr. Charles A. Sims of California Cryobanks Family Cord Blood Services Named to National Stem Cell Advisory Council
5. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
6. Informed Medical Communications Appoints Charles T. Saldarini to Board of Directors
7. Leading Lobbying Firm Celebrates Growth and New Name: Troutman Sanders Strategies
8. Squire Sanders Stands Out in Independent Analysis of Law Firms in Europe
9. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
10. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
11. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... LEXINGTON, Mass. , March 22, 2017   ... collections, today announced that Doctors Pathology Service ... mid-Atlantic region of the United States ... the Delaware Health Information Network (DHIN) to ... researchers. The novel program, announced in ...
(Date:3/22/2017)... TORONTO , March 22, 2017 /PRNewswire/ - ... Therapeutics (the "Company" or "Propellon"), a start-up created ... WDR5-targeted anti-cancer therapeutics. FACIT,s investment, combined with non-dilutive ... lead program. The seed funding enables Propellon to ... position the Company for financing and/or entering a ...
(Date:3/22/2017)... ... ... Premier executive recruitment firm, Slone Partners, is proud to have been named a Top ... Hunt Scanlon Media is one of the most respected life science publications in the ... sector. , “It is a great honor for Slone Partners to be part of ...
(Date:3/22/2017)... , ... March 21, 2017 , ... Benchworks ... Chief Executive Officer Forum on March 23-24 in San Diego. The event is ... and diagnostic industries. , Benchworks Vice President Christian Meyer will also participate in ...
Breaking Biology Technology:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 ... Family of Companies (Avamere Health Services, Infinity Rehab, Signature ... research study that will apply the power of IBM ... living and health centers. By analyzing data streaming from ... insights into physical and environmental conditions, and obtain deeper ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):